Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer.

Asian J Androl · 2017 · PMC6337943 · PMID 29286005

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the ASCENT study, docetaxel in combination with high-dose Vitamin D was used in mCRPC patients and showed a trend toward increased SRE-free survival (planned secondary end point). 34 Time to SRE and SSE was not assessed as an exploratory end point in the most recent studies of docetaxel.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.